Abstract: Described are cementitious reagent materials produced from globally abundant inorganic feedstocks. Also described are methods for the manufacture of such cementitious reagent materials and forming the reagent materials as microspheroidal glassy particles. Also described are apparatuses, systems and methods for the thermochemical production of glassy cementitious reagents with spheroidal morphology. The apparatuses, systems and methods make use of an in-flight melting/quenching technology such that solid particles are flown in suspension, melted in suspension, and then quenched in suspension. The cementitious reagents can be used in concrete to substantially reduce the CO2 emission associated with cement production.

Abstract: The present invention relates to fiber cement flooring products. In particular, the present invention provides fiber cement flooring products, at least comprising cement and fibers, characterized in that these fiber cement flooring products comprise amorphous silica in an amount of between about 2 weight % and about 15 weight % compared to the total dry weight of the fiber cement composition of said fiber cement flooring product. The present invention further relates to methods for the production of such fiber cement flooring products as well as uses of such fiber cement flooring products in the building industry. The present invention further relates to fiber cement formulations and fiber cement materials, which are suitable for the production of fiber cement products for flooring applications.

Abstract: A plurality of granules comprising particulate silicate material bonded together with an inorganic binder, the inorganic binder comprising reaction product of at least alkali silicate and hardener, wherein the hardener is at least one of aluminum phosphate, amorphous aluminosilicate, fluorosilicate, Portland cement, or a calcium silicate, wherein the particulate silicate material is present as at least 50 percent by weight of each granule, based on the total weight of the respective granule, wherein each granule has a total porosity in a range from greater than 0 to 50 percent by volume, based on the total volume of the respective granule, and wherein the granules have Tumble Toughness Value of at least 70 before immersion in water and at least 40 after immersion in water at 20° C.±2° C. for two months. The granules are useful, for example, as roofing granules.

Abstract: Roofing granules comprising agglomerated inorganic material, and building materials, such as shingles, that include such roofing granules. By fabricating roofing granules from agglomerating inorganic material it is possible to tailor the particle size distribution so as to provide optimal shingle surface coverage, thus reducing shingle weight and usage of raw materials. Additionally, the use of agglomeration permits the utilization of by-products from conventional granule production processes.

Abstract: A method of reducing sulfur concentration in fly ash, flue gas desulfurization (FGD) ash, and mixtures thereof by contacting the fly ash, FGD ash, or mixtures thereof with an aqueous acidic solution, for a time, at a temperature, and at a liquid-to-solid ratio wherein the sulfur concentration within the fly ash, FGD ash, or mixture thereof is reduced to no more than 5 wt % SO3 based on the total weight of dry fly ash, FGD ash, or mixture thereof so treated.

Abstract: A waterproofing system including a functional layer S1 including 10-80 wt.-% of at least one thermoplastic polymer P1 and 10-80 wt.-% of at least one solid particulate filler F, wherein the surface of the functional layer S1 has an Auto-correlation length of waviness W(Sal) of at least 50 ?m. Further, a method for producing a waterproofing system and to the use of a mechanical surface treatment step to increase the waviness factor, determined as the ratio of the Root mean square roughness of waviness W(Sq) to the square of the Auto-correlation length of waviness W(Sal), of a surface of a functional layer S1.

Abstract: A method for making a carbonated precast concrete product includes: obtaining a mixture including at least one binder material, an aggregate, and water; molding the mixture into a molded intermediate; demolding the molded intermediate to obtain a demolded intermediate, the demolded intermediate having a first water-to-binder ratio; conditioning the demolded intermediate to provide a conditioned article having a second water-to-binder ratio less than the first water-to-binder ratio of the demolded intermediate; moisturizing at least one surface of the conditioned article with an aqueous medium, thereby causing a weight gain of the conditioned article and providing a moisturized product, a first portion of the moisturized product having a third water-to-binder ratio greater than a fourth water-to-binder ratio of a remainder of the moisturized product; and curing the moisturized product with carbon dioxide to obtain the carbonated precast concrete product.

Abstract: A method for fabricating a component according to an example of the present disclosure includes the steps of depositing a stoichiometric precursor layer onto a preform, and densifying the preform by depositing a matrix material onto the stoichiometric precursor layer. An alternate method and a component are also disclosed.

Abstract: A bulk animal bedding material is presented comprising shredded and fiberized natural lignocellulosic material vigorously blended with a solvent and small grain particles (SGPs) to form twisted, curled, clumped, and rolled fibers with the SGPs integrated within and/or encasing said fibers.

Abstract: Disclosed is a process for making a fully water-soluble granule comprising humic acid and a microbial community composition. Disclosed also is a fully water-soluble granule comprising humic acid and a microbial community composition. Such a granule is useful as an organic aid to crop growth, particularly in applications where solubility is desirable or necessary.

Abstract: A process and system for the conversion of a feedstock comprising C3-C5 light alkanes to a C5+ hydrocarbon product, for example, a BTX-rich hydrocarbon product, by performing the alkane activation (first-stage) and the oligomerization/aromatization (second-stage) in separate stages, which allows each conversion process to occur at optimal reaction conditions thus increasing the overall hydrocarbon product yield. The alkane activation or first-stage is operated at a higher temperature than the second-stage since light alkanes are much less reactive than light olefins. Since aromatization of olefins is more efficient at higher pressure, the second-stage is maintained at a higher pressure than the first-stage. Further, fixed-bed catalysts are used in each of the first-stage and the second-stage.

Abstract: A catalyst composition includes a metal catalyst dispersed in a molten eutectic mixture of alkali metal or alkaline earth metal carbonates or hydroxides. A process for the catalytic cracking of hydrocarbons includes contacting in a reactor system a carbon-containing feedstock with at least one catalyst in the presence of oxygen to generate olefinic and/or aromatic compounds; and collecting the olefinic and/or aromatic compounds; wherein: the at least one catalyst includes a metal catalyst dispersed in a molten eutectic mixture of alkali metal or alkaline earth metal carbonates or hydroxides. A process for preparing the catalyst includes mixing metal catalyst precursors selected from transition metal compounds and rare-earth metal compounds and a eutectic mixture of alkali metal or alkaline earth metal carbonates or hydroxides and heating it. A use of the catalyst in the catalytic cracking process of hydrocarbons.

Abstract: A process for synthesising methanol is described comprising the steps of (i) passing a feed gas comprising a make-up gas containing hydrogen and carbon dioxide to a methanol synthesis loop, (ii) recovering a product gas mixture containing methanol from the methanol synthesis loop, (iii) cooling the product gas mixture to below the dew point to condense crude methanol, (iv) separating the crude methanol from an unreacted gas mixture, (v) passing a portion of the unreacted gas mixture to the methanol synthesis loop and (vi) recovering a portion of the unreacted gas mixture as a purge gas stream, characterised by contacting the crude methanol and a portion of the purge gas in a stripping unit to strip dissolved gases from the crude methanol thereby forming a stripped crude methanol and an enriched gas mixture, and feeding at least a portion of the enriched gas mixture to the methanol synthesis loop.

Abstract: The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

Abstract: A process for production of malic acid includes obtaining a feed that includes one or more of crude maleic anhydride, pure maleic anhydride, crude maleic acid, crude fumaric acid, pure maleic acid, pure fumaric acid, vent gas scrubber solutions from production of maleic anhydride, and vent gas scrubber solutions from production of phthalic anhydride. The feed is passed in a tubular reactor assembly to obtain a first product stream, which includes unreacted feed and malic acid. The feed is made to undergo hydration reaction in the tubular reactor assembly for a first predetermined time period, and further hydration of the first product stream is caused in a stirred tank reactor assembly for a second predetermined time period to obtain a final product stream, which includes the malic acid.

Abstract: Lactic acid is obtained by a method including (A) a step of continuous fermentation wherein a fermentation culture medium of a microorganism having an ability of lactic acid fermentation is filtered through a porous membrane having an average pore size of not less than 0.01 ?m and less than 1 ?m with a transmembrane pressure difference within the range of 0.1 to 20 kPa, and the permeate is collected, while retaining the non-permeated liquid in or returning the non-permeated liquid to the culture, and adding a fermentation feedstock to the culture; (B) a step of filtering the permeate obtained in Step (A) through a nanofiltration membrane; and (C) a step of distilling the permeate obtained in Step (B) under a pressure of not less than 1 Pa and not more than atmospheric pressure, at 25° C. to 200° C. to recover lactic acid.

Abstract: A method of preparing an ester by reacting a carboxylic acid with a (C1-C36)alcohol in the presence of a catalyst that is suitable for preparing carboxylic acid esters of monomeric carboxylic acids in high yield. The method reduces by-products of the reaction, in particular esters of dimeric, trimeric and/or oligomeric carboxylic acids. The method requires a minimal excess of alcohol and does not require removal of water and/or carboxylic acid ester from the reaction mixture. The method is particularly suitable for the reaction of hydroxyalkylcarboxylic acids and fatty alcohols.

Abstract: The present invention is directed to a purification method for purifying a fluorine-containing polymerizable monomer of the formula (1), in which the fluorine-containing polymerizable monomer is purified by distillation in the coexistence of a phenolic compound A such as 6-tert-butyl-2,4-xylenol and a phenolic compound B such as 2,2?-methylene-bis(4-methyl-6-tert-butylphenol). By the combined use of the phenolic compound A and the phenolic compound B, it is possible to significantly suppress polymerization or oligomerization of the fluorine-containing polymerizable monomer even during industrial-production-scale distillation and efficiently purify the fluorine-containing polymerizable monomer by distillation.

Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Abstract: Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

Abstract: Provided are a novel compound capable of improving the luminous efficiency, stability and lifespan of a device, an organic electronic element using the same, and an electronic device thereof.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

Abstract: Provided herein are compounds of formula I, compositions comprising the compounds and method of treating various diseases with the compounds and compositions.

Abstract: This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy.

Abstract: The present invention provides a method for producing high-purity 5-methyl-1H-tetrazole in high yield.

Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.

Abstract: The present disclosure provides a preparing method for 5-alkoxymethylfurfural, including steps of (a) preparing fructose, (b) mixing the fructose, an organic acid catalyst, and an organic solvent, thereby preparing mixing solution, and (c) heating the mixing solution, thereby preparing 5-alkoxymethylfurfural. Therefore, 5-alkoxymethylfurfural may be effectively prepared without by-products from fructose.

Abstract: A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.

Abstract: The disclosure provides methods and compositions for providing shatter formulations taking the form of crystalline polymorphs, where methods of preparation include preparing tetrahydrocannabinol acid (THCA) powder followed by decarboxylating THCA and removal of terpenes.

Abstract: An improved process for producing various types of cannabis extract from harvested cannabis wherein a quantity of harvested cannabis, which typically includes the inflorescence, floral leaves, and small stems of a flowering cannabis plants, is frozen and subjected to cryogenic grinding to produce pulverized cannabis. The pulverized cannabis is then subjected to alcohol extraction to produce an initial cannabis extract which is filtered to yield a remainder fraction and a filtrate. The remainder fraction potentiates the activity of cannabis formulations while the filtrate can be subjected to one of several forms of further processing according to the desired chemical profile of the final product.

Abstract: A Reflux Rinsing method for purifying crystals using solvent vapor through dynamic equilibrium recrystallization. Feed material having tetrahydrocannabinol acid (THCA) is inserted into a reaction vessel having walls, and upper portion, and a lower portion with a bottom surface. The feed material is exposed to a hydrocarbon liquid in the reaction vessel in a quantity sufficient to keep liquid present in equilibrium with gas in the reaction vessel through the recrystallization process, forming a raw extract having THCA. The walls and bottom surface of the reaction vessel are coated with raw extract. The reaction vessel is heated and then the heating is discontinued. Vapor/thin-film DER is promoted in the reaction vessel for a predetermined length of time with no solvent reflux, resulting in formation of purified crystals of THCA under pressure. The hydrocarbon solvent is reclaimed from the reaction vessel, leaving the purified crystals and impurities.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: Provided are compounds of Formula Y-Z: The compounds target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

Abstract: An organic compound is disclosed comprising: a first chemical moiety with a structure of formula I, and two second chemical moieties, each with a structure of formula II, wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract: The present invention disclosed a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof.

Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxylic acids and esters of the general formula (I) and their agrochemically acceptable salts and to their use in the crop protection sector.

Abstract: The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.

Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.

Abstract: Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.

Abstract: Disclosed in the present invention are a pyrazolo [1,5-a]pyrimidine derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating diseases associated with tropomyosin receptor kinases, in particular for preventing or treating cancers associated with tropomyosin receptor kinases. Each substituent in formula (I) has the same definition as that in the description.